[go: up one dir, main page]

AU2002330039A1 - Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer - Google Patents

Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

Info

Publication number
AU2002330039A1
AU2002330039A1 AU2002330039A AU2002330039A AU2002330039A1 AU 2002330039 A1 AU2002330039 A1 AU 2002330039A1 AU 2002330039 A AU2002330039 A AU 2002330039A AU 2002330039 A AU2002330039 A AU 2002330039A AU 2002330039 A1 AU2002330039 A1 AU 2002330039A1
Authority
AU
Australia
Prior art keywords
methods
cancer
modulators
diagnosis
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002330039A
Inventor
Daniel Afar
Natasha Aziz
Kurt C. Gish
Peter A. Hevezi
David H. Mack
Keith E. Wilson
Albert Zlotnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EOS Biotechnology Inc
Original Assignee
EOS Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EOS Biotechnology Inc filed Critical EOS Biotechnology Inc
Publication of AU2002330039A1 publication Critical patent/AU2002330039A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G01N33/57545—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2002330039A 2001-09-17 2002-09-17 Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer Abandoned AU2002330039A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US32346901P 2001-09-17 2001-09-17
US60/323,469 2001-09-17
US32388701P 2001-09-20 2001-09-20
US60/323,887 2001-09-20
US35066601P 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US35525702P 2002-02-08 2002-02-08
US35514502P 2002-02-08 2002-02-08
US60/355,257 2002-02-08
US60/355,145 2002-02-08
US37224602P 2002-04-12 2002-04-12
US60/372,246 2002-04-12
PCT/US2002/029560 WO2003025138A2 (en) 2001-09-17 2002-09-17 Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

Publications (1)

Publication Number Publication Date
AU2002330039A1 true AU2002330039A1 (en) 2003-04-01

Family

ID=27559718

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002330039A Abandoned AU2002330039A1 (en) 2001-09-17 2002-09-17 Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

Country Status (5)

Country Link
EP (1) EP1434881A4 (en)
JP (1) JP2005518782A (en)
AU (1) AU2002330039A1 (en)
CA (1) CA2459219A1 (en)
WO (1) WO2003025138A2 (en)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE425249T1 (en) 2000-06-16 2009-03-15 Biogen Idec Inc RENAL REGULATORY ELEMENTS AND THEIR USE
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
NZ530457A (en) 2001-06-01 2007-12-21 Biogen Idec Inc Molecules and methods for inhibiting shedding of KIM-1
WO2003043565A2 (en) * 2001-09-24 2003-05-30 University Of Aarhus Methods for diagnosis and treatment of diseases associated with altered expression of nrf2
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DE60220621T2 (en) 2001-11-09 2008-03-06 Proteologics, Inc. Posh nucleic acid, polypeptides and related methods
WO2003080856A2 (en) * 2002-03-19 2003-10-02 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2003222965A1 (en) * 2002-04-05 2003-10-27 University Court Of The University Of Edinburgh Schizophrenia associated genes
AU2003278137A1 (en) 2002-06-20 2004-01-06 Bristol-Myers Squibb Company Identification and regulation of a g-protein coupled receptor, rai-3
GB0215224D0 (en) * 2002-07-01 2002-08-14 Inpharmatica Ltd Protein
CN1717413A (en) * 2002-11-12 2006-01-04 惠氏公司 Novel PTH responsive gene
AU2003299925B2 (en) 2002-12-30 2011-10-27 Biogen Ma Inc. KIM-1 antagonists and use to modulate immune system
JP4462964B2 (en) * 2003-03-10 2010-05-12 第一三共株式会社 Antibodies targeting cancer-specific antigens
EP1615991A4 (en) 2003-04-03 2007-12-19 Bristol Myers Squibb Co Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v
EP1923401A3 (en) * 2003-04-14 2008-08-20 Novartis AG Gene expression associated with osteoblast differentiation
US20080038247A1 (en) * 2003-05-05 2008-02-14 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated With G-Protein-Coupled Receptor Gpr39 (Gpr39)
WO2005001049A2 (en) * 2003-06-06 2005-01-06 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific genes and proteins
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
NZ547633A (en) 2003-11-06 2010-08-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005066363A2 (en) * 2004-01-09 2005-07-21 Medigen Biotechnology Corporation Cancer specific gene ccndbp1
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
GB0404209D0 (en) * 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
WO2005085860A2 (en) * 2004-02-27 2005-09-15 Institut Curie New proliferation markers in clinical practice and their use for cancer prognosis or diagnosis
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
EP1741792B1 (en) 2004-04-27 2010-11-03 Takeda Pharmaceutical Company Limited Novel ligand of g-protein-conjugated receptor protein and use thereof
EP1747467A1 (en) * 2004-05-11 2007-01-31 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 6 (dpp6)
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
US7371384B2 (en) 2004-07-20 2008-05-13 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein antibody
EP1771474B1 (en) 2004-07-20 2010-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
KR101270829B1 (en) 2004-09-23 2013-06-07 제넨테크, 인크. Cystein engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
CN103751780A (en) 2005-03-02 2014-04-30 比奥根艾迪克Ma公司 KIM-1 antibodies for treatment of TH2-mediated conditions
AU2006238475B2 (en) * 2005-04-18 2012-09-27 Opsona Therapeutics Limited Toll-like receptor 14 (TLR14 ) and use thereof
WO2007008647A2 (en) * 2005-07-07 2007-01-18 Vanderbilt University Diagnosing and grading gliomas using a proteomics approach
AU2006320654A1 (en) * 2005-11-29 2007-06-07 Yupo Ma Targeting of SALL4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS)
NZ569236A (en) 2005-12-08 2012-06-29 Medarex Inc Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and their use
AU2007254005B2 (en) 2006-02-10 2012-11-29 Genentech, Inc. Anti-FGF19 antibodies and methods using same
UA100969C2 (en) 2006-03-21 2013-02-25 Дженентек, Інк. Combinatorial therapy involving alpha5beta1 antagonists
WO2008054534A2 (en) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
WO2007141796A2 (en) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
US7851144B2 (en) 2006-08-18 2010-12-14 The University Of Washington Compositions and methods for detecting cancer
GB0620695D0 (en) * 2006-10-18 2006-11-29 Opsona Therapeutics Composition and methods for the treatment of nurdegenerative disease
GB0620705D0 (en) 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
EP1932854A1 (en) * 2006-12-15 2008-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lysosomal associated membrane protein (LAMP) - like polypeptide, ligands to the same, and use of the same in the frame of detection and purification of human plasmacytoid dendritic cells
EP2152903A2 (en) * 2007-04-26 2010-02-17 Ludwig Institute for Cancer Research, Ltd. Methods for diagnosing and treating astrocytomas
CN103360466B (en) 2007-07-27 2016-08-03 伊玛提克斯生物技术有限公司 Antitumor related peptides and relevant anti-cancer vaccine compositions
EP2188310B1 (en) 2007-08-03 2017-02-08 Genentech, Inc. Humanized anti-fgf19 antagonists and methods using same
CA2736170A1 (en) 2007-09-06 2009-03-12 Case Western Reserve University Methods for diagnosing and treating cancers
KR20100065162A (en) 2007-09-26 2010-06-15 제넨테크, 인크. Novel antibodies
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
EP2303332B1 (en) 2008-07-15 2014-12-31 Genentech, Inc. Anthracycline conjugates, process for their preparation and their use as antitumor compounds
WO2010044952A2 (en) * 2008-08-25 2010-04-22 Centocor Ortho Biotech Inc. Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders
JP5606322B2 (en) 2008-10-20 2014-10-15 昇志 佐藤 Tumor antigen peptide and use thereof
EP2865689A1 (en) 2008-12-08 2015-04-29 Compugen Ltd. FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
AU2014201027B2 (en) * 2008-12-08 2015-11-19 Compugen Ltd. FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
BRPI1006270B1 (en) 2009-03-25 2022-08-16 Genentech, Inc ANTI-A5SS1 ANTIBODY, IMMUNOCONJUGATE, PHARMACEUTICAL COMPOSITION, IN VITRO OR EX VIVO METHOD TO DETECT A5SS1 PROTEIN, USE OF AN ANTIBODY AND KIT TO DETECT A5SS1 PROTEIN
IN2012DN03025A (en) 2009-09-09 2015-07-31 Ct Se Llc
JP5918540B2 (en) 2010-01-29 2016-05-18 中外製薬株式会社 Anti-DLL3 antibody
SG183335A1 (en) 2010-02-23 2012-09-27 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
EP2528625B1 (en) 2010-04-15 2013-07-10 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
JP2013534520A (en) 2010-06-08 2013-09-05 ジェネンテック， インコーポレイテッド Cysteine engineered antibodies and conjugates
CN103313990B (en) 2010-11-17 2016-07-20 基因泰克公司 Alanyl maytansinol antibody coupling matter
CN103608684B (en) 2011-05-12 2016-05-04 基因泰克公司 A Multiple Reaction Monitoring LC-MS/MS Method for the Detection of Therapeutic Antibodies in Animal Samples Using Framework Signature Peptides
RS54446B1 (en) 2011-10-14 2016-06-30 Medimmune Limited PIROLOBENZIDIAZEPINE AND ITS CONJUGATES
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
HRP20181817T1 (en) 2012-02-15 2018-12-28 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
SI2814844T1 (en) 2012-02-15 2017-10-30 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
RU2015106946A (en) 2012-08-02 2016-09-27 Дженентек, Инк. ANTIBODIES TO TYPE B ENDOTHELIN RECEPTOR (ETBR) AND THEIR IMMUNO CONJUGATES
US9464141B2 (en) 2012-08-02 2016-10-11 Genentech, Inc. Anti-ETBR antibodies and immunoconjugates
ES2530968T3 (en) 2012-10-12 2015-03-09 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
PT2906251T (en) 2012-10-12 2017-12-04 Medimmune Ltd CONJUGATES OF PYRROLOBENZODIAZEPINA-ANTIBODY ANTI-CD22
TR201808051T4 (en) 2012-10-12 2018-06-21 Adc Therapeutics Sa Pyrrolobenzodiazepine antibody conjugates.
JP6270859B2 (en) 2012-10-12 2018-01-31 エイディーシー・セラピューティクス・エス・アー・エール・エルＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａｒｌ Pyrrolobenzodiazepine-antibody conjugate
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
CA2887895C (en) 2012-10-12 2019-10-29 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd19 antibody conjugates
CA2894961C (en) 2012-12-21 2020-09-15 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EA032986B1 (en) 2012-12-21 2019-08-30 Медимьюн Лимитед Pyrrolobenzodiazepines
CA2904044C (en) 2013-03-13 2020-03-31 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2014140174A1 (en) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
LT2970473T (en) 2013-03-14 2017-10-25 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
EP3033111B1 (en) 2013-08-12 2019-03-13 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
MX2016007578A (en) 2013-12-16 2016-10-03 Genentech Inc 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.
BR112016013861A2 (en) 2013-12-16 2017-10-10 Genentech Inc drug and antibody conjugates, compounds, treatment method and pharmaceutical composition
JP6671292B2 (en) 2013-12-16 2020-03-25 ジェネンテック， インコーポレイテッド Peptidomimetic compounds and antibody-drug conjugates thereof
KR102641268B1 (en) 2014-07-17 2024-02-27 노보 노르디스크 에이/에스 Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
JP6531166B2 (en) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugate
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
JP6622293B2 (en) 2014-09-12 2019-12-18 ジェネンテック， インコーポレイテッド Anthracycline disulfide intermediates, antibody-drug conjugates, and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
PE20170905A1 (en) 2014-09-17 2017-07-12 Genentech Inc PYROLOBENZODIAZEPINES AND ANTIBODY-DISULFIDE CONJUGATES THEREOF
JP6878287B2 (en) 2014-11-25 2021-05-26 アーデーセー セラピューティクス ソシエテ アノニム Pyrrolobenzodiazepine-antibody conjugate
WO2016090050A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 The drug of the total antibody of multichannel and antibody conjugate quantifies measuring method
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
CN109476648B (en) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 Sevelamer antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
ES2871001T3 (en) 2017-02-08 2021-10-28 Adc Therapeutics Sa Conjugates of pyrrolobenzodiazepines and antibodies
KR102189731B1 (en) 2017-04-18 2020-12-11 메드임뮨 리미티드 Pyrrolobenzodiazepine conjugate
MX2019012464A (en) 2017-04-20 2019-12-11 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate.
BR112019026564A2 (en) 2017-06-14 2020-06-30 Adc Therapeutics Sa dosing regimens for administration of an anti-cd19 adc
AU2018316532B2 (en) 2017-08-18 2022-11-24 Medimmune Limited Pyrrolobenzodiazepine conjugates
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thailanstatin analogs
US11667713B2 (en) 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
MA52190A (en) 2018-04-02 2021-02-17 Bristol Myers Squibb Co ANTI-TREM-1 ANTIBODIES AND ASSOCIATED USES
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP7708662B2 (en) 2018-10-24 2025-07-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Conjugated chemical degraders and methods of use
CN113227119A (en) 2018-12-10 2021-08-06 基因泰克公司 Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
KR102890251B1 (en) 2019-03-15 2025-11-25 메드임뮨 리미티드 Azetidobenzodiazepine dimers and conjugates comprising the same for use in the treatment of cancer
TWI799824B (en) 2020-03-31 2023-04-21 日商中外製藥股份有限公司 Dll3-targeting multispecific antigen-binding molecules and uses thereof
CN115698340A (en) * 2020-04-08 2023-02-03 建喾立嗣股份公司 Composition and application thereof for diagnosing colorectal cancer, rectal cancer or colorectal adenoma using GLRB gene CPG methylation changes
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
TW202241925A (en) * 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 Peptides displayed by hla for use in immunotherapy against different types of cancers
CN114113603B (en) * 2021-06-30 2023-11-17 四川大学华西医院 Application of CYTL1 as gastric cancer prognosis marker
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
TW202432187A (en) 2022-12-23 2024-08-16 美商建南德克公司 Cereblon degrader conjugates, and uses thereof
CN121263210A (en) 2023-04-17 2026-01-02 沛科生物公司 Antibodies and antibody-drug conjugates, as well as their usage, synthesis processes, and intermediates
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
WO2000028090A2 (en) * 1998-11-12 2000-05-18 Nyxis, Inc. Diagnostic assay for cancer
US6426186B1 (en) * 2000-01-18 2002-07-30 Incyte Genomics, Inc Bone remodeling genes

Also Published As

Publication number Publication date
EP1434881A2 (en) 2004-07-07
WO2003025138A2 (en) 2003-03-27
JP2005518782A (en) 2005-06-30
CA2459219A1 (en) 2003-03-27
EP1434881A4 (en) 2005-10-26
WO2003025138A3 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
AU2002330039A1 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
AU2002309583A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002245317A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
AU2002347428A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2002215345A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
AU2002252144A1 (en) Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
AU2002257004A1 (en) Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU2001231199A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2002251844A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002249871A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
WO2003022987A9 (en) Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
AU2001290902A1 (en) Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
AU2002231979A1 (en) Modulators of p53-p300 interactions and screening methods therefor
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU3755300A (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002364708A1 (en) Novel compositions and methods for cancer
AU2001252945A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
AU2002239431A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001290518A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase